

TRAIL Trimer Protein, Human, Recombinant (His & Flag)

General Information

Synonyms:	TRAIL;Apo-2L;APO2L;TL2;Apo-2 ligand;CD253;TNFSF10
Protein Construction:	Gly118-Gly281
Species:	Human
Expression Host:	HEK293 Cells
Accession:	P50591-1
Molecular Weight:	60 kDa (predicted). Due to glycosylation, the protein migrates to 55-65 kDa based on Tris-Bis PAGE result.

QC Testing

Biological Activity:	Immobilized TRAIL Trimer, His Tag at 2 μ g/ml (100 μ l/well) on the plate. Dose response curve for Human TRAIL R1, hFc Tag with the EC50 of 49.2ng/ml determined by ELISA.
Purity:	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Endotoxin:	< 1.0 EU/ μ g of the protein as determined by the LAL method.
Formulation:	Lyophilized from a solution filtered through a 0.22 μ m filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization.

Preparation and Storage

Reconstitution:

Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μ g/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

Protein Background

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily that can initiate the apoptosis pathway by binding to its associated death receptors DR4 and DR5. The activation of the TRAIL pathway in inducing tumor-selective apoptosis leads to the development of TRAIL-based cancer therapies, which include recombinant forms of TRAIL, TRAIL receptor agonists, and other therapeutic agents.

Reference

Yuan X, et al. Developing TRAIL/TRAIL death receptor-based cancer therapies. Cancer Metastasis Rev. 2018 Dec;37(4):733-748. doi: 10.1007/s10555-018-9728-y. PMID: 29541897; PMCID: PMC6138568.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481